Year: 2023

If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1   The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2 A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC, or under the skin) Tecentriq® (atezolizumab). Tecentriq SC can be injected in approximately seven minutes, with most injections taking between four and eight...

Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMDStudy confirms subretinal prothesis feasible and well-tolerated with no reduction of natural peripheral vision, confirming 36-month results Patients suffering from central vision loss reliably recognized letters and sequences of letters, a clinically significant improvement Full data readout of accompanying pivotal PRIMAvera trial expected early 2024 Pixium Vision reiterates that it is subject to receivership proceedings and is actively seeking buyers for its assetsParis, France, 14, 2023 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, today announces data from a first in human...

LHV Group’s October results were driven by the profitable operations of all subsidiaries and the pre-financing of subordinated loans. The consolidated deposits of AS LHV Group increased by EUR 69 million in October. Fixed-term deposits increased by EUR 105 million (EUR 27 million of which growth in deposits through platforms), while demand deposits decreased by EUR 35 million. The Group’s consolidated loan portfolio increased by EUR 49 million in October. Retail loans increased by EUR 13 million and corporate loans by EUR 36 million. The volume of funds managed by LHV increased by EUR 1 million over the month. A total of 5.2 million payments from financial intermediary clients were processed in the course of the month. In October, the consolidated net profit of AS LHV Group was EUR 11.2 million. In October, AS LHV Pank earned EUR 11.5...

Bigbank AS (registry code 10183757, address Riia tn 2, Tartu, 51004) (Bigbank) hereby announces a public offering of its unsecured subordinated bonds (Offering). The Offering is conducted on the basis of the prospectus drawn up by Bigbank and registered by the Estonian Financial Supervision and Resolution Authority (FSA) on 13 November 2023, that has been disclosed on the date of this announcement on the web pages of Bigbank and the FSA (Prospectus). During the Offering bonds are offered that form the first series in the Bigbank unsecured subordinated bond programme (Programme). Under the Offering Bigbank plans to raise up to 3 million euros with the option of increasing the amount up to 10 million euros. Under the Programme it is possible for Bigbank to raise up to 30 million euros in total. Main terms of the Offering During the Offering,...

 Top line results expected in Q2 2024Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the last patient has been randomized in Cohort 2 of the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024. The primary efficacy endpoint of this study is time to baseline monthly seizure count. The trial is being conducted in collaboration with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company. As previously announced...

HighlightsBiological on-off events have impacted production and results. Action taken to reduce biological risks Low harvest volume in the quarter to focus on rebuilding biomass Milestone reached in Newfoundland, where we in October conducted our very first harvest Expansion of post-smolt in Finnmark to accelerate post-smolt strategy 78% of the harvested volume in the quarter ASC certified Expect harvest of 25,800 tonnes in Q4 2023. Total volume of 76,000 tonnes in 2023, increasing to 85,000 tonnes in 2024 Financial results Operational EBIT for Grieg Seafood was NOK -86 million in the third quarter of 2023, compared to NOK 145 million in the corresponding period last year. Harvest volume was 12,245 tonnes in the period (22,923), which gives an operational EBIT per kg of NOK -7.0 (6.3). Commenting on the quarter, Andreas Kvame, CEO...

Leveraging Signature Aviation’s Book-and-Claim solution, the initiative reduces the annual greenhouse gas emissions associated with fuel in Bombardier’s flight operations by approximately 20 to 25 %. The Book-and-Claim model guarantees a rigorous accounting of greenhouse gas emission reductions while optimizing logistics. Bombardier continues to lead the way and take concrete actions to ensure a sustainable future for business aviation.MONTRÉAL, Nov. 13, 2023 (GLOBE NEWSWIRE) — Bombardier is proud to cement its industry leadership in sustainability by reaffirming its commitment to cover all its operational flights with sustainable aviation fuel (SAF), utilizing the Book-and-Claim system. One year after announcing its landmark agreement with Signature Aviation, Bombardier continues to demonstrate its firm engagement to drive...

MENLO PARK, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (the “Company” or “Runway Growth”), a specialty finance company focused on providing senior secured loans to high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products and other high-growth industries, today announced the pricing of the previously announced underwritten secondary offering of 3,750,000 shares of its common stock by OCM Growth Holdings LLC and Oaktree Opportunities Fund XB Holdings (Delaware), L.P. (collectively, the “Selling Stockholders”), pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”), at a public offering price of $12.56 per share. In connection with the offering, the...

HOUSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings at the BofA Securities Global Energy Conference on Wednesday, November 15, 2023 in Houston, TX. A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events. About Targa Resources Corp. Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary domestic midstream infrastructure...